Bacterial and Viral Specimen Collection Market Report 2026

The bacterial and viral specimen collection market size has grown rapidly in recent years. It will grow from $23.86 billion in 2025 to $27.14 billion in 2026 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to increasing incidence of infectious diseases, expansion of diagnostic testing volumes, growth of centralized laboratory testing, rising awareness of proper specimen handling, improvements in sample transport infrastructure.

The bacterial and viral specimen collection market size is expected to see rapid growth in the next few years. It will grow to $44.98 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to growing demand for rapid diagnostic testing, expansion of decentralized healthcare services, increasing adoption of molecular diagnostics, rising focus on pandemic preparedness, growth in research on emerging pathogens. Major trends in the forecast period include increasing demand for sterile and standardized collection kits, rising adoption of transport media with extended stability, growing focus on infection control protocols, expansion of home-based and point-of-care collection solutions, enhanced emphasis on sample integrity and traceability.

The rising prevalence of infectious diseases is expected to drive the growth of the bacterial and viral specimen collection market going forward. Infectious diseases are conditions caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can spread directly or indirectly from person to person. The increasing prevalence of infectious diseases is largely fueled by growing urbanization, which results in higher population density and closer human contact, promoting faster disease transmission and creating favorable conditions for pathogens to spread more easily within communities. Bacterial and viral specimen collection supports infectious disease management by providing critical samples that enable accurate detection and diagnosis, allowing for timely and targeted medical interventions. For instance, in March 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, tuberculosis cases rose from 8,320 in 2022 to 9,615 in 2023, an increase of 1,295 cases, while the incidence rate grew from 2.5 to 2.9 per 100,000 persons, reflecting a significant upward trend over the year. Therefore, the rising prevalence of infectious diseases is fueling the growth of the bacterial and viral specimen collection market.

Major companies operating in the bacterial and viral specimen collection market are focusing on introducing innovative solutions, such as viral DNA and RNA extraction kits, to enhance the efficiency, accuracy, and speed of pathogen detection and analysis. A viral DNA and RNA extraction kit is a laboratory tool used to isolate and purify viral genetic material from clinical samples for precise molecular testing and diagnosis. For instance, in April 2024, New England Biolabs, a US-based life sciences company, launched the Monarch Mag Viral DNA and RNA Extraction Kit, a magnetic bead-based purification kit designed for rapid, reliable, and highly sensitive extraction of viral DNA and RNA from sample types such as saliva, respiratory swabs, and wastewater (with enrichment). The kit supports manual and automated workflows compatible with platforms like KingFisher Flex and Agilent Bravo, enabling high-throughput processing. It improves detection sensitivity for low viral loads, includes carrier RNA for better recovery, and is suitable for downstream applications including qPCR, RT-qPCR, ddPCR, and next-generation sequencing (NGS). The solution addresses demands in infectious disease testing, viral genome sequencing, and environmental surveillance with scalable, hands-free workflows.

In April 2024, Eurofins Scientific SE, a Luxembourg-based testing laboratory company, acquired Ascend Clinical LLC for an undisclosed amount. Through this acquisition, Eurofins Scientific aims to strengthen its presence in renal and transplant testing in the United States, expand its clinical client base, and enhance patient care by integrating Ascend's expertise with Eurofins' extensive laboratory network, technological capabilities, and geographic reach. Ascend Clinical LLC is a US-based clinical laboratory company specializing in infectious disease testing, including bacterial and viral specimen collection and analysis.

Major companies operating in the bacterial and viral specimen collection market are Roche Diagnostics International AG, Thermo Fisher Scientific Inc., Becton Dickinson and Company, Lonza Group AG, Hologic Inc., bioMérieux SA, Quidel Corporation, QIAGEN N.V., DiaSorin S.p.A., Greiner Bio-One International GmbH, Spectrum Solutions LLC, Hardy Diagnostics Inc., EKF Diagnostics Holdings Plc, Trinity Biotech Plc, Puritan Medical Products Company LLC, Wuxi NEST Biotechnology Co. Ltd., Copan Diagnostics Inc., VIRCELL S.L., Medical Wire & Equipment Co. Ltd., HiMedia Laboratories Pvt. Ltd., Longhorn Vaccines and Diagnostics LLC, Beaver Biomedical Engineering Co. Ltd.

North America was the largest region in the bacterial and viral specimen collection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bacterial and viral specimen collection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bacterial and viral specimen collection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the bacterial and viral specimen collection market by increasing costs of imported swabs, transport media, plastic consumables, sterile packaging materials, and cold-chain logistics components. Hospitals and diagnostic laboratories in North America and Europe are most affected due to reliance on imported consumables, while Asia-Pacific faces pricing pressure in large-scale production. These tariffs are increasing procurement costs and straining testing budgets. However, they are also encouraging local manufacturing of collection kits, regional supply chain diversification, and investment in domestic diagnostic consumable production.

The bacterial and viral specimen collection market research report is one of a series of new reports that provides bacterial and viral specimen collection market statistics, including bacterial and viral specimen collection industry global market size, regional shares, competitors with a bacterial and viral specimen collection market share, detailed bacterial and viral specimen collection market segments, market trends and opportunities, and any further data you may need to thrive in the bacterial and viral specimen collection industry. This bacterial and viral specimen collection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bacterial and viral specimen collection refers to the careful process of obtaining biological samples, such as swabs from the nose or throat, body fluids, or tissue samples, to detect, identify, and study bacterial or viral pathogens responsible for infections. This process requires the use of sterile equipment, correct collection techniques, and proper storage or transport methods to ensure the microorganisms remain intact and viable for accurate laboratory analysis.

The primary product types of bacterial and viral specimen collection are bacterial specimen collection and viral specimen collection. Bacterial specimen collection involves obtaining biological samples from a patient using aseptic procedures to detect, isolate, and identify disease-causing bacteria. These products and processes are applied in various applications, including diagnostics and research, and are used by end users such as hospitals and clinics, diagnostic laboratories, academic and research institutions, and others.

The bacterial and viral specimen collection market consists of revenues earned by entities by providing services, such as microbiological sampling, blood sample collection, specimen transport, documentation and data management, and quality assurance. The market value includes the value of related goods sold by the service provider or included within the service offering. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.